Funding for this research was provided by:
Helse Sør-Øst RHF (52009/8029)
Sixth Framework Programme (LSHM-CT-2003-502941)
Lovisenberg Diakonale Sykehus
Foundation for the National Institutes of Health (AG15833, AG00831, AG18409)
Eli Lilly and Company
Received: 14 January 2022
Accepted: 19 September 2022
First Online: 1 October 2022
: All participants provided written informed consent. The study was approved by the Norwegian Regional Ethical Committee (REK no: 2010/2539) and was conducted according to the Declaration of Helsinki.
: Not applicable.
: The authors declare that they have no competing interests.